Publications

5808 Results

Phase II trial of the epidermal growth factor receptor (EGFR) inhibitor erlotinib (E) in patients (pts) with advanced papillary renal cell carcinoma (pRCC)--SWOG S0317

Authors
C Pan;M Hussey;P Lara;PC Mack;RB Nagle;J Dutcher;W Samlowski;J Clark;ED Crawford;MS Gordon
Journal / Conference
Proc of the American Society of Clinical Oncology, Journal of Clinical Oncology 25(18S):#15516
Year
2007
Research Committee(s)
Genitourinary
Study Number(s)
S0317

Erlotinib as initial therapy in patients with advanced non-small cell lung cancer (NSCLC) and a performance status (PS) of 2: A SWOG phase II trial (S0341)

Authors
PJ Hesketh;K Chansky;AJ Wozniak;P Mack;PN Lara;WA Franklin;FR Hirsch;J Crowley;DR Gandara
Journal / Conference
Proc of the American Society of Clinical Oncology, Journal of Clinical Oncology 25(18S):#7536
Year
2007
Research Committee(s)
Lung
Study Number(s)
S0341

A phase II randomized selection trial evaluating concurrent chemotherapy plus cetuximab or chemotherapy followed by cetuximab in patients with advanced non-small cell lung cancer (NSCLC): final report of SWOG 0342

Authors
RS Herbst;K Chansky;K Kelly;JN Atkins;AM Davies;SR Dakhil;KS Albain;ES Kim;JJ Crowley;DR Gandara
Journal / Conference
Proc of the American Society of Clinical Oncology, Journal of Clinical Oncology 25(18S):#7545
Year
2007
Research Committee(s)
Lung
Study Number(s)
S0342

Clinical and molecular factors predictive of outcome with first-line sorafenib-based therapy in advanced renal carcinoma (RCC): an analysis of SWOG 0412

Authors
BH Goldman;PN Lara Jr;TM Beer;PC Mack;HA Drabkin;WS Holland;ED Crawford;CW Ryan
Journal / Conference
Proc of the American Society of Clinical Oncology, Journal of Clinical Oncology 25(18S):#5108
Year
2007
Research Committee(s)
Genitourinary
Study Number(s)
S0412

S0413: a phase II SWOG study of GW572016 (lapatinib) as first line therapy in patients (pts) with advanced or metastatic gastric cancer

Authors
S Iqbal;B Goldman;HJ Lenz;CM Fenoglio-Preiser;CD Blanke
Journal / Conference
Proc of the American Society of Clinical Oncology, Journal of Clinical Oncology 25(18S):#4621
Year
2007
Research Committee(s)
Gastrointestinal
Study Number(s)
S0413

A phase II trial of sorafenib in patients with recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC). a Southwest Oncology Group (SWOG) trial.

Authors
SK Williamson;J Moon;CH Huang;P Guaglianone;GT Wolf;SG Urba
Journal / Conference
Proc of the American Society of Clinical Oncology, Journal of Clinical Oncology 25(18S):#6044
Year
2007
Research Committee(s)
Head and Neck
Study Number(s)
S0420

SWOG 0514: a phase II study of sorafenib (BAY 43-9006) as single agent in patients (pts) with unresectable or metastatic gallbladder cancer or cholangiocarcinomas

Authors
AB El-Khoueiry;C Rankin;HJ Lenz;P Philip;SE Rivkin;CD Blanke
Journal / Conference
Proc of the American Society of Clinical Oncology, Journal of Clinical Oncology 25(18S):#4639
Year
2007
Research Committee(s)
Gastrointestinal
Study Number(s)
S0514

Phase II trial of imatinib mesylate in recurrent, biomarker positive, ovarian cancer (Southwest Oncology Group Protocol S0211) [PMID17343607]

Authors
DS Alberts;PY Liu;SP Wilczynski;A Jang;J Moon;JH Ward;JT Beck;M Clouser;M Markman
Journal / Conference
International Journal of Gynecological Cancer 17:784-788
Year
2007
Research Committee(s)
Gynecologic
Study Number(s)
S0211

Chemotherapy in patients >80 with advanced non-small cell lung cancer: combined results from SWOG 0027 and LUN 6 [PMID17545843]

Authors
PJ Hesketh;RC Lilenbaum;K Chansky;A Dowlati;P Graham;RA Chapman;JJ Crowley;DR Gandara
Journal / Conference
Journal of Thoracic Oncology 2(6):494-498
Year
2007
Research Committee(s)
Lung
Study Number(s)
S0027

Gemcitabine and irinotecan for patients with untreated extensive stage small cell lung cancer: SWOG 0119 [PMID17545848]

Authors
W Akerley;J McCoy;PJ Hesketh;JW Goodwin;JD Bearden;JN Atkins;K Chansky;JJ Crowley;DR Gandara
Journal / Conference
Journal of Thoracic Oncology 2(6):526-530
Year
2007
Research Committee(s)
Lung
Study Number(s)
S0119